Stem cell treatment for poor graft function after transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests whether giving special stem cells (called mesenchymal stem cells) can help improve poor graft function after a stem cell transplant. It aims to boost your blood cell counts so you recover better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 and no older than 60 years old.
- You need to be a candidate for a stem cell transplant (bone marrow or cord blood).
- Your performance status (how well you can do daily activities) should be good, with an expected survival of more than 3 months.
- You must not have severe heart, kidney, or liver problems, or other active cancers.
- You need to be free of uncontrolled infections and not have serious allergic reactions.
- You must be willing to participate and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving extra stem cells from your original donor can help your blood cell counts recover after a transplant. It is for people whose new immune system has not fully engrafted or whose counts are dangerously low.
This study tests whether umbilical cord blood cells can help patients whose blood counts have dropped again after a stem cell transplant. It may be an option for people who have recovered initially but later develop low blood cell levels.
This study tests whether an experimental cell therapy called iMSC can help prevent graft-versus-host disease (a common complication after a stem cell transplant). It is given soon after your transplant, within 5 days of enrolling, and aims to reduce the chance of this serious condition.
This study tests whether a single infusion of stem cells from bone marrow is safe for people with chronic kidney disease (CKD). It aims to see if this treatment can help slow kidney function loss.
This trial tests a stem cell transplant that uses specially selected cells (CD34+ cells) to treat myelodysplastic syndrome (MDS), a blood disorder. The transplant comes from a donor and aims to replace unhealthy blood-forming cells with healthy ones, which may slow or stop the disease. It is designed for patients with higher-risk MDS or certain high-risk features.
This trial is testing an experimental treatment using special cells called clonal fetal mesenchymal stem cells (cfMSCs) to help control overactive immune responses. The goal is to reduce symptoms of immune disorders like graft-versus-host disease (GVHD) when other treatments have not worked.
Hear when a new MSC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.